Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Canada ready to discuss COVID-19 vaccine IP waiver, 'not interfering or blocking' -Trudeau

Published 05/07/2021, 08:17 AM
Updated 05/07/2021, 04:30 PM
© Reuters. Healthcare workers prepare doses of the Pfizer/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, at Woodbine Racetrack pop-up vaccine clinic in Toronto, Ontario, Canada May 5, 2021. REUT

By David Ljunggren and Steve Scherer

OTTAWA (Reuters) - Canada is ready to discuss an intellectual property rights (IP) waiver for COVID-19 vaccines and will not block one even though it stresses the importance of protecting patents, officials said on Friday.

U.S. President Joe Biden on Wednesday threw his support behind waiving IP rights for COVID-19 vaccines. Any such waiver would have to be negotiated through the World Trade Organization (WTO).

"We've been working with partners at the WTO to find a consensus-based solution and are ready to discuss proposals, in particular for COVID-19 vaccines," Prime Minister Justin Trudeau told reporters.

Biden's proposal angered pharmaceutical companies. Firms working on vaccines have reported sharp revenue and profit gains during the crisis.

Canadian International Trade Minister Mary Ng earlier said that Ottawa firmly believed in the importance of protecting IP.

"I can assure you Canada is not interfering or blocking. Canada is very much working to find a solution," said Trudeau, who did not give details of the Canadian negotiating stance.

Ng said Ottawa recognized how much the pharmaceutical industry had done to innovate COVID-19 vaccines, adding that many barriers to access were unrelated to IP, such as supply-chain constraints.

Canada is trying to quell a third wave of the coronavirus pandemic that is pushing some healthcare systems to breaking points, particularly in the western provinces of Alberta and Manitoba.

Manitoba officials said they were postponing some non-urgent surgeries to open space for COVID-19 patients and planned to announce tougher public health restrictions as daily cases soared to a near-record high.

The U.S. state of Montana will offer vaccines to around 2,000 Alberta truckers who regularly cross the border, Alberta Premier Jason Kenney said.

© Reuters. Healthcare workers prepare doses of the Pfizer/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, at Woodbine Racetrack pop-up vaccine clinic in Toronto, Ontario, Canada May 5, 2021. REUTERS/Carlos Osorio

Truckers will get vaccinated at a post being set up just south of the border, using Montana's surplus Johnson & Johnson (NYSE:JNJ) vaccines.

The scheme mirrors an agreement that Saskatchewan and Manitoba reached with North Dakota.

Latest comments

When public health is at high risk generic labs ought to simply negotiate deals where they pay royalties and government taxation ought to be waived.
Is that not a win win solution?
India gets the ip waiver if they promise they will cleanse their streets of human excrement, clean the ganges river, cut down on pollution and arrest them irs scammers.
IP's that cannot serve humanity, have nothing useful to be protected for.
Talking like a robber
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.